Engineered immune cells take on Hard-to-Treat colon cancer
Disease control
Recruiting now
This early-phase study tests a new treatment called CNA3103 for people with metastatic colorectal cancer that has not responded well to standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. Th…
Phase: PHASE1, PHASE2 • Sponsor: Carina Biotech Limited • Aim: Disease control
Last updated May 08, 2026 12:02 UTC